NCT03813784View on ClinicalTrials.gov

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

885

Participants

Timeline

Start Date

March 7, 2019

Primary Completion Date

June 7, 2023

Study Completion Date

June 7, 2023

Conditions
Gastric CancerGastroEsophageal Cancer
Interventions
DRUG

SHR-1210

Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial

DRUG

Capecitabine

1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.

DRUG

Oxaliplatin

130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.

DRUG

Apatinib

250 mg administered as continuous oral once daily (QD) of each 3-week cycle.

Trial Locations (1)

Unknown

Beijing Cancer Hospital, Peking University, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03813784 - A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy | Biotech Hunter | Biotech Hunter